RENO, Nev., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today announced that it has closed a private placement of approximately $5 million (the “Private Placement”); however, $250,000 of subscriptions, from certain members of management and the Board of Directors, are being held in escrow pending approval by the Company’s stockholders as required under Nasdaq Listing Rule 5635(c).

内华达州里诺市，2026年10月15日（环球电讯社）——临床前阶段的医疗器械与再生医学公司Conexeu Sciences Inc.（纳斯达克股票代码：CNXU）（“Conexeu”或“公司”），正在推进其研究性组织修复平台CXU™，今日宣布已完成一项金额约为500万美元的私募配售（“本次私募配售”）；然而，来自部分管理层成员及董事会成员的25万美元认购款项正由第三方托管，待公司股东根据纳斯达克上市规则第5635(c)条的要求批准后予以释放。

Upon receipt of the required stockholder approval, the securities will be issued to the certain members of management and certain directors, and the $250,000 will be released to the Company. If stockholder approval is not obtained, the escrowed funds will be returned to the management and director subscribers, and the securities will not be issued to them.

在获得所需的股东批准后，证券将向某些管理层成员和某些董事发行，25万美元将释放给公司。如果未获得股东批准，托管资金将退还给认购的管理层和董事，证券也不会向他们发行。

The Private Placement consists of 1,666,667 units (each, a “Unit”) at a price of $3.00 per Unit, with each Unit consisting of one share of common stock (a “Share”) and one warrant (a “Warrant”) to purchase one share of common stock at an exercise price of $3.00 per share, exercisable for 24 months from the date of issuance.

本次私募配售包括1,666,667个单位（每个称为“单位”），每单位价格为3.00美元，每个单位由一股普通股（称为“股份”）和一份认股权证（称为“认股权证”）组成，该认股权证允许以每股3.00美元的行权价格购买一股普通股，自发行之日起24个月内可行使。

For certain Canadian subscribers, the Company has issued special warrants (“Special Warrants”) instead of Units at $3.00 per Special Warrant, whereby each Special Warrant shall automatically be converted (without any further action or payment on the part of the holder) into one Share and one Warrant upon the earlier of (a) the date on which the final Canadian prospectus qualifying the distribution of the Units and underlying Shares and Warrants in British Columbia, Canada is receipted by the British Columbia Securities Commission, an.

对于某些加拿大订阅者，本公司以每份特别认股权证3.00美元的价格发行了特别认股权证（“特别认股权证”），而非单位。根据该安排，每份特别认股权证将在以下较早日期自动转换为（无需持有人采取进一步行动或支付任何款项）一股股份和一份认股权证：(a) 不列颠哥伦比亚省证券委员会收到最终加拿大招股说明书之日，该招股说明书符合在不列颠哥伦比亚省分销单位及基础股份和认股权证的资格要求。

The Private Placement was led by existing shareholders, including members of Conexeu’s management team and certain directors, among them Miles Harrison, President, Chief Executive Officer and Director, and David Bogart, Chief Commercial Officer and Director.

本次私募配售由现有股东领投，包括Conexeu管理团队成员及部分董事，其中涵盖总裁、首席执行官兼董事Miles Harrison，以及首席商业官兼董事David Bogart。

Conexeu intends to use the net proceeds from the Private Placement for working capital and general corporate purposes, including but not limited to continued manufacturing scale-up, regulatory testing and preclinical work intended to support its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten Minute Tissue™, the Company’s lead wound care device candidate..

Conexeu 计划将私募配售的净收益用于营运资金和一般企业用途，包括但不限于持续扩大生产规模、进行监管测试以及开展临床前工作，以支持其针对主导伤口护理器械候选产品 Ten Minute Tissue™ 向美国食品药品监督管理局（“FDA”）提交的计划中的 510(k) 上市前通知。

The financing follows the Company’s Oct. 6, 2026, program update, in which Conexeu reported that multiple scaled-up batches of CXU™ material met predefined Company specifications and that the Company remains on track to make its planned 510(k) submission in the first calendar quarter of 2027.

此次融资紧随公司于2026年10月6日发布的项目更新之后。在该更新中，Conexeu报告称，多批放大的CXU™材料均符合公司预先设定的规格标准，且公司仍按计划于2027年第一季度提交510(k)申请。

No placement agent was engaged, and no commissions were paid in connection with the Private Placement. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) covering the resale of the Shares and the shares of common stock issuable upon exercise of the Warrants (each, a “Warrant Share”).

未聘请任何配售代理，也未就本次私募支付任何佣金。公司已同意向美国证券交易委员会（“SEC”）提交一份注册声明，涵盖股份的转售以及行使认股权证时可发行的普通股股份（每份此类股份称为“认股权证股份”）。

Additional information regarding the Private Placement will be included in a Current Report on Form 8-K to be filed with the SEC on EDGAR..

有关本次私募配售的更多信息将包含在将通过EDGAR系统向美国证券交易委员会（SEC）提交的8-K表格当前报告中。

The Units, Special Warrants, Shares, Warrants and Warrant Shares (collectively, the “Securities”) have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws. Accordingly, the Securities of the Company may not be offered or sold in the United States or to, or for the benefit of, “U.S.

单位、特别认股权证、股份、认股权证及认股权证股份（统称为“证券”）并未根据经修订的《1933年证券法》（以下简称“《证券法》”）或任何州证券法律进行注册。因此，本公司的证券不得在美国境内向“美国人士”或其利益相关方发行或出售。

persons” (as defined in Regulation S under the Securities Act) absent registration or an applicable exemption from such registration requirements of the Securities Act and applicable state securities laws. The Securities are “restricted securities” as defined in Rule 144(a)(3) under the Securities Act.

“人士”（定义见《证券法》下的S条例），除非已根据《证券法》及适用的州证券法进行注册或适用豁免。该等证券为《证券法》下第144(a)(3)条所定义的“受限证券”。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any Securities, nor shall there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful..

本新闻稿不构成出售任何证券的要约，也不构成购买任何证券的要约邀请；在任何此类要约、要约邀请或销售属违法的司法管辖区，均不得进行任何证券的销售。

About Conexeu Sciences Inc.

关于 Conexeu Sciences Inc.

Architecting Bioregeneration™.

构建生物再生™。

Conexeu Sciences

Conexeu Sciences

is a preclinical-stage medical device and regenerative medicine company. Our patented extracellular matrix (ECM) platform, CXU™, is built on a single structural principle and is designed to support bioregeneration: one formula, one device, designed to scale across multiple addressable markets.

是一家处于临床前阶段的医疗器械与再生医学公司。我们拥有专利的细胞外基质（ECM）平台 CXU™ 基于单一结构原理构建，旨在支持生物再生：一种配方、一种器械，设计用于在多个可触达市场中实现规模化应用。

Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market.

Conexeu 的目标市场是规模达数十亿美元的大型终端市场，包括伤口护理、牙周应用以及面部和身体组织修复（涵盖 GLP-1 减肥后可能出现的组织变化），并在 3D 打印和生物制造工作流程以及兽医市场拥有进一步的扩张机会。

The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in the first calendar quarter of 2027 for its initial indication, subject to regulatory review..

公司正在推进一项基于等同对比的美国监管策略，预计将于2027年第一季度提交其首个适应症的510(k)申请，待监管机构审评。

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

Conexeu 由一支经验丰富的领导团队带领，该团队在生物材料、再生医学以及医疗器械的商业化与开发方面拥有深厚的专业知识。

About CXU™

关于 CXU™

CXU™ is designed to support soft tissue lost through injury, aging, and the tissue changes that can follow GLP-1 weight loss. The Company's lead device candidate, Ten Minute Tissue™, is a thermosensitive extracellular matrix (ECM) that remains fluid at room temperature and is designed to transition to a stable gel in situ at body temperature within approximately ten minutes.

CXU™旨在支持因损伤、衰老以及GLP-1减肥后可能出现的组织变化而流失的软组织。公司的主要候选器械Ten Minute Tissue™是一种热敏性细胞外基质（ECM），在室温下保持液态，并设计为在体温条件下于约十分钟内原位转变为稳定的凝胶。

In preclinical research, Ten Minute Tissue™ has been characterized for host cell infiltration, vascular ingrowth, organized remodeling, and a low-inflammatory profile, conditions intended to support constructive remodeling. .

在临床前研究中，Ten Minute Tissue™ 已被表征具有宿主细胞浸润、血管长入、有序重塑以及低炎症反应的特征，这些条件旨在支持建设性重塑。

[1]

[1]

The platform is grounded in more than a decade of university preclinical research and protected by a multi-jurisdictional patent estate spanning more than 40 jurisdictions (U.S., EU, Japan, and Australia, with protection pending in Canada). Conexeu owns the platform IP, holding all rights, title, and interest, with no royalty or licensing obligations, and intends to expand across new indications and markets..

该平台基于十余年的大学临床前研究，并由覆盖全球40多个司法管辖区（包括美国、欧盟、日本和澳大利亚，加拿大的保护正在申请中）的专利组合提供保护。Conexeu拥有该平台的全部知识产权，享有所有权利、所有权和权益，无需支付任何特许权使用费或承担许可义务，并计划拓展新的适应症和市场。

Sources

来源

[1] Hartwell R., Leung V., Chavez-Munoz C., et al.

[1] 哈特韦尔 R.，梁 V.，查韦斯-穆尼奥斯 C.，等

A novel hydrogel-collagen composite improves functionality of an injectable extracellular matrix.

一种新型水凝胶-胶原蛋白复合物改善了可注射细胞外基质的功能。

Acta Biomaterialia (2011); 7; 3060-3069.

《生物材料学报》（2011年）；第7卷；3060-3069页。

The cited study [1] is preclinical. Preclinical results are not necessarily predictive of clinical outcomes. Ten Minute Tissue™ is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. The cited study did not evaluate CXU™ specifically in wound care indications; wound care applications represent the design-intent application of the underlying CXU™ platform, and supporting evidence in indication-specific preclinical models is being developed by the Company..

引用的研究[1]属于临床前研究。临床前结果并不一定能够预测临床结局。Ten Minute Tissue™ 是一款在研医疗器械，尚未获得美国食品药品监督管理局的许可或批准。所引用的研究并未专门评估 CXU™ 在伤口护理适应症中的表现；伤口护理应用是底层 CXU™ 平台的设计预期用途，公司正在针对特定适应症的临床前模型开发相应的支持性证据。

Trademarks.

商标。

CXU™, Ten Minute Tissue™, and Architecting Bioregeneration™ are trademarks of Conexeu Sciences Inc.

CXU™、Ten Minute Tissue™ 和 Architecting Bioregeneration™ 是 Conexeu Sciences Inc. 的商标。

Investor and Media Contacts:

投资者与媒体联系人：

Gateway Group

网关组

CNXU@Gateway-grp.com

CNXU@Gateway-grp.com

949-574-3860

949-574-3860

astr partners

astr 合作伙伴

josh.barer@astrpartners.com

josh.barer@astrpartners.com

908-578-6478

908-578-6478

Safe Harbor Statement

安全港声明

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States securities laws. These statements relate to analysis and other information that are based on forecasts or future results, estimates of amounts not yet determinable, and assumptions of management, including, but not limited to, statements regarding the anticipated use of proceeds from the Private Placement, the expected receipt of stockholder approval and release of the escrowed subscription proceeds, the filing of a resale registration statement, regulatory pathway, submission timing, category development and platform expansion.

除本文所载的历史事实陈述外，本新闻稿中呈现的信息构成适用美国证券法所定义的“前瞻性陈述”。这些陈述涉及基于预测或未来结果、对尚未确定金额的估计以及管理层假设的分析和信息，包括但不限于关于私募配售所得款项的预期用途、预计获得股东批准及释放托管认购款项、提交转售注册声明、监管路径、提交时间、品类开发及平台扩张的陈述。

Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”.

任何其他表述或涉及对预测、期望、信念、计划、预测、目标、假设或未来事件或表现的讨论的陈述（通常，但并非总是，使用诸如“预期”或“不预期”、“预计”、“预见”或“不预见”、“计划”、“估计”或“打算”等词语或短语，或声明某些行动、事件或结果“可能”、“能够”、“会”、“或许”或“将”被采取、发生或实现）均非历史事实陈述，应被视为“前瞻性陈述”。

We have based these forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Our actual future results may differ materially from those discussed or implied in our forward-looking statements for various reasons.

这些前瞻性陈述基于我们对未来事件或表现的当前预期。尽管我们认为这些预期是合理的，但此类前瞻性陈述本质上存在风险和不确定性，其中许多超出我们的控制范围。由于各种原因，我们的实际未来结果可能与前瞻性陈述中讨论或暗示的结果存在重大差异。

Factors that could contribute to such differences include, but ar.

可能导致此类差异的因素包括，但不限于。